Pharma Mar S.A.
Biopharmaceutical company developing oncology treatments from marine sources.
PHM | MC
Overview
Corporate Details
- ISIN(s):
- ES0169501022 (+1 more)
- LEI:
- 959800QWKZ45ZQC2AV58
- Country:
- Spain
- Address:
- Avenida de los Reyes 1 Polígono Industrial La Mina, 28770 Colmenar Viejo
- Website:
- https://pharmamar.com/en/
- Sector:
- Manufacturing
Description
Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-02-28 00:00 |
Corporate Governance Report - Pharma Mar S.A.
|
Spanish | 693.1 KB | ||
| 2024-02-28 00:00 | English | 1.5 MB | |||
| 2024-02-28 00:00 | Spanish | 6.8 MB | |||
| 2024-02-28 00:00 | Spanish | 14.4 MB | |||
| 2024-02-09 08:25 |
Sylentis, filial de Pharma Mar, informa que el ensayo clínico de fase III con t…
|
Spanish | 116.8 KB | ||
| 2024-01-31 19:05 |
La Sociedad informa de las operaciones de adquisición de acciones propias en el…
|
Spanish | 300.8 KB | ||
| 2024-01-30 17:35 |
La Sociedad informa de cambios en la presidencia de la Comisión de Nombramiento…
|
Spanish | 27.3 KB | ||
| 2024-01-08 17:37 |
La Sociedad informa de las operaciones de adquisición de acciones propias en el…
|
Spanish | 273.0 KB | ||
| 2023-12-18 08:26 |
Sylentis, filial de Pharma Mar, anuncia que el estudio FYDES para evaluar la se…
|
Spanish | 120.2 KB | ||
| 2023-12-12 14:33 |
La Sociedad anuncia que su socio Luye Pharma Group Ltd ha recibido la aprobació…
|
Spanish | 111.8 KB | ||
| 2023-12-05 17:38 |
La Sociedad informa de las operaciones de adquisición de acciones propias en el…
|
Spanish | 233.1 KB | ||
| 2023-12-04 08:31 |
La Sociedad anuncia que su socio Luye Pharma Group Ltd ha recibido la aprobació…
|
Spanish | 98.2 KB | ||
| 2023-11-07 08:26 |
La Sociedad anuncia que su socio Adium Pharma ha recibido la aprobación para la…
|
Spanish | 102.6 KB | ||
| 2023-11-06 17:37 |
La Sociedad informa de las operaciones de adquisición de acciones propias en el…
|
Spanish | 348.0 KB | ||
| 2023-10-31 08:28 |
Pharma Mar inicia un ensayo clínico de fase IIb/III con Zepzelca® (lurbinectedi…
|
Spanish | 108.8 KB |
Automate Your Workflow. Get a real-time feed of all Pharma Mar S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pharma Mar S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pharma Mar S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
